Compugen Ltd. (CGEN)

NASDAQ: CGEN · IEX Real-Time Price · USD
2.130
-0.130 (-5.75%)
At close: Apr 12, 2024, 4:00 PM
2.080
-0.050 (-2.35%)
After-hours: Apr 12, 2024, 4:04 PM EDT
-5.75%
Market Cap 190.70M
Revenue (ttm) 33.46M
Net Income (ttm) -18.75M
Shares Out 89.53M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 388,381
Open 2.230
Previous Close 2.260
Day's Range 2.090 - 2.260
52-Week Range 0.530 - 3.030
Beta 2.68
Analysts Strong Buy
Price Target 7.25 (+240.38%)
Earnings Date May 13, 2024

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 68
Stock Exchange NASDAQ
Ticker Symbol CGEN
Full Company Profile

Financial Performance

In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CGEN stock is "Strong Buy." The 12-month stock price forecast is $7.25, which is an increase of 240.38% from the latest price.

Price Target
$7.25
(240.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

4 days ago - PRNewsWire

Compugen to Participate in Two Upcoming Investor Conferences

HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

11 days ago - PRNewsWire

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

4 weeks ago - PRNewsWire

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

5 weeks ago - PRNewsWire

Compugen Reports Fourth Quarter and Full Year 2023 Results

Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple da...

5 weeks ago - PRNewsWire

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

6 weeks ago - PRNewsWire

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

HOLON, Israel , Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd.

7 weeks ago - PRNewsWire

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

2 months ago - PRNewsWire

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...

Other symbols: AZN
3 months ago - PRNewsWire

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today th...

3 months ago - PRNewsWire

Compugen stock rockets on anti-tumor drug deal with Gilead

Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage develop...

Other symbols: GILD
4 months ago - Market Watch

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- C...

Other symbols: AZN
4 months ago - PRNewsWire

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer im...

4 months ago - PRNewsWire

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program.

Other symbols: GILD
4 months ago - Business Wire

Compugen Reports Third Quarter 2023 Results

Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in co...

Other symbols: AZN
5 months ago - PRNewsWire

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations m...

5 months ago - PRNewsWire

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today th...

5 months ago - PRNewsWire

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer

COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor si...

5 months ago - PRNewsWire

Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023

HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...

6 months ago - PRNewsWire

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

Other symbols: KMDAPLXTAROTEVA
6 months ago - Market Watch

Compugen to Present at Single Cell Genomics 2023 Meeting

HOLON, Israel , Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, i...

6 months ago - PRNewsWire

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

HOLON, Israel , Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

6 months ago - PRNewsWire

Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

HOLON, Israel , Sept. 27, 2023 /PRNewswire/ -- Compugen Ltd.

7 months ago - PRNewsWire

Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HOLON, Israel , Aug. 31, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

8 months ago - PRNewsWire

Compugen Reports Second Quarter 2023 Results

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer; initial f...

8 months ago - PRNewsWire